职场创业

    今日:233| 主题:45638
收藏本版
IT、互联网、电子商务创业经验、建议、管理等知识分享。

[其他] What it's like when Alphabet's venture arm invests in your startup —

[复制链接]
范德萨 发表于 2016-10-3 03:34:06
159 3

立即注册CoLaBug.com会员,免费获得投稿人的专业资料,享用更多功能,玩转个人品牌!

您需要 登录 才可以下载或查看,没有帐号?立即注册

x

What it's like when Alphabet's venture arm invests in your startup —  -1 (something,investing,beginning,surprise,research)
  Zach Weinberg, left, and Nat Turner, the founders of Flatiron Health. Saskia Uppenkamp  
  After a year of working at Google, Nat Turner and Zach Weinberg were getting restless.
  The duo — which came to Google in 2010 after it acquired their company, Invite Media — was ready to start thinking about their next venture, doing research on the side and angel investing in other startups to see what worked and what didn't. They had never intended to stay at Google long, something they had made clear from the beginning.
  "It was no surprise we were going to leave, everyone knew that," Turner told Business Insider. "I think we told our boss three months after we got to Google that we were only going to be there until the two-year mark."
  Before that two-year mark, Turner and Weinberg were approached by what at the time was called Google Ventures — now called simply GV. GV, which is Alphabet's early-stage venture arm, wanted to meet some of the young entrepreneurs who had sold their companies to Google and find out what they were doing next. By then, Turner and Weinberg had started to think about starting a healthcare company after Turner's cousin was diagnosed with leukemia.
   About a month later, the pair traveled to Boston, where they met with Krishna   Yeshwant, a practicing physician who also works as a partner at GV. Turner said he pitched Yeshwant a few "very terrible" healthcare ideas, which spawned the beginning of what is now Flatiron Health: a software company that  organizes the world’s oncology information and makes it accessible for doctors, patients, and researchers.  
   'The complexity was an advantage'

  After the first meeting, Yeshwant began introducing Turner and Weinberg to everyone within his circles in the medical community.
  "It wasn’t just like, ‘Hey, here’s an email intro,’" Turner said. "He actually came to a lot of those meetings. We were still 24 and working at Google and had no healthcare background, so him being a physician added a lot of credibility to the room."

What it's like when Alphabet's venture arm invests in your startup —  -2 (something,investing,beginning,surprise,research)
  Krishna Yeshwant, a partner at GV. GV  
  At the same time, Turner and Weinberg were traveling to cancer care centers around the country, shadowing doctors and finding out what it's really like to be both a patient and a physician in cancer care. Turner estimates that they traveled to more than 50 centers in cities like Greenville, South Carolina; Jacksonville, Florida; and Rutgers, New Jersey.
  "A lot of time when people start companies, especially in oncology or clinical medicine, they spend time in the big academic centers and they forget that 80% to 90% of the care of patients is delivered in community oncology centers," Yeshwant told Business Insider. "Those are often places that would be considered flyover country — they’re not in the big cities. Nat and Zach went to those places and they realized the complexity. I think to them, to some degree, the complexity was an advantage."
  Yeshwant says that the fact that neither founder had a background in healthcare was a selling point to him. Since he's a physician, a lot of the healthcare startups are sent in his direction, but most of the time, entrepreneurs get scared off by the complexity and the amount of capital it would take to start a company in that field.
  Yeshwant ended up leading both Flatiron Health's Series A and Series B rounds — $8 million and $130 million respectively. The company remains GV's biggest investment ever, second only to Uber.
   'A profoundly exciting area'

   Yeshwant is confident that if Flatiron Health stays focused on oncology — an industry he says is " going through an amazing renaissance right now" — the company could become massively successful.
   "We’re developing and understanding the biology behind cancer that’s letting us really develop treatments that are working — and potentially cures down the line," Yeshwant said. " If all Flatiron ever does is touch some part of oncology, it has the potential to be a tens of billions, or hundreds of billions-size company. Oncology alone is the size of the advertising industry, if not larger."
   In January, the company raised a   $175 million Series C round, led by Roche Pharmaceuticals. Flatiron's most recent valuation is around $ 983 million, putting it just shy of the "unicorn" threshold.   
   But Turner seems focused on something much simpler than becoming a billion-dollar company at the moment:  "We just want science to move faster in cancer."
友荐云推荐




上一篇:Tech companies and the global rise of e-sports
下一篇:Let’s stop name-dropping our corporate exes
酷辣虫提示酷辣虫禁止发表任何与中华人民共和国法律有抵触的内容!所有内容由用户发布,并不代表酷辣虫的观点,酷辣虫无法对用户发布内容真实性提供任何的保证,请自行验证并承担风险与后果。如您有版权、违规等问题,请通过"联系我们"或"违规举报"告知我们处理。

ptyks 发表于 2016-10-3 05:23:04
男人,再优秀,没女人也生不下孩子。说明:”合作很重要!”
回复 支持 反对

使用道具 举报

luckyyey 发表于 2016-10-5 19:10:19
佩服佩服!
回复 支持 反对

使用道具 举报

电商令狐冲 发表于 2016-10-17 00:40:54
连广告也信,读书读傻了吧
回复 支持 反对

使用道具 举报

*滑动验证:
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

我要投稿

推荐阅读

扫码访问 @iTTTTT瑞翔 的微博
回页顶回复上一篇下一篇回列表手机版
手机版/CoLaBug.com ( 粤ICP备05003221号 | 文网文[2010]257号 )|网站地图 酷辣虫

© 2001-2016 Comsenz Inc. Design: Dean. DiscuzFans.

返回顶部 返回列表